Abstract:AMPK activation appears in a healthy liver during fasting in response to energy generation needs. AMPK enhances FA oxidation and autophagy, reducing lipid accumulation. mTORC1 activation occurs in high food intake in a diseased liver, leading to lipogenesis, reducing FA oxidation, lipolysis, and autophagy, leading to liver lipid accumulation and NAFLD. ACC2, acetyl‐Coa carboxylase 2; AKT, protein kinase B; AMPK, AMP‐activated protein kinase; CPT1, carnitine palmitoyl transferase I; DNL, de novo lipogenesis; FA, fatty acid; GTP, GTPase‐activating protein; HSL, hormone‐sensitive lipase; IR, insulin receptor; LKB, liver kinase B; mTOR, mechanistic target of rapamycin; NAFLD, non‐alcoholic fatty liver disease; PGC‐1α, peroxisome proliferator‐activated receptor‐gamma coactivator‐1 alpha; PI3K, phosphoinositide 3‐ kinase; PPARa, peroxisome proliferator‐activated receptors alpha; RHEB, Ras homolog enriched in the brain; TSC, tuberous sclerosis complex; ULK1, unc‐51‐like kinase 1. Obesity is related to several organs, but the liver is particularly affected. Adenosine monophosphate‐activated protein kinase (AMPK) is a cellular energy sensor and regulator of liver lipid dysfunction and glucose metabolism. The mechanistic target of rapamycin (mTOR) is a protein kinase regulating cell growth, survival, metabolism, and immunity. Together, these pathways are involved in obesity, insulin resistance, non‐alcoholic fatty liver disease (NAFLD) and its progression, and autophagy. During energy demand, liver kinase B (LKB) phosphorylation helps activate the AMPK/mTOR pathways. Likewise, the protein forkhead box O family (FOXO) negatively regulates adipogenesis by binding to the promoter sites of peroxisome proliferator‐activated receptor‐gamma coactivator 1‐alpha, initiating adipogenesis. In addition, acetyl‐CoA carboxylase, which regulates de novo lipogenesis, is linked to LKB and FOXO in developing NAFLD. The kinase complex, consisting of Unc‐51‐like autophagy‐activating kinase 1 or 2 (ULK1, ULK2) by stimulating autophagy, and eliminating fat droplets in NAFLD, is regulated by mTORC1 and negatively regulated by AMPK that suppresses liver lipogenesis and increases fatty acid oxidation. Also, ULK1 is essential for initiating phagophore formation, establishing macrophagy, and generating autophagosomes. The selective breakdown of lipid droplets through macroautophagy, or macrolipophagy, occurs on a cellular energy level using free fatty acids. In addition, mTORC1 promotes lipogenesis by activating sterol regulatory element‐binding protein. Finding new components and novel regulatory modes in signaling is significant for a better understanding of the AMPK/mTOR pathways, potentially facilitating the development of future diagnostic and therapeutic strategies for NAFLD and its progression to non‐alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma.

mTOR: A Potential New Target in Nonalcoholic Fatty Liver Disease

Macrophage Raptor Deficiency-Induced Lysosome Dysfunction Exacerbates Nonalcoholic Steatohepatitis

An Endoplasmic Reticulum Stress-MicroRNA-26a Feedback Circuit in NAFLD

Activation of Mtorc1 Disrupted LDL Receptor Pathway: a Potential New Mechanism for the Progression of Non-Alcoholic Fatty Liver Disease.

NAFLD-associated hepatocellular carcinoma (HCC) - A compelling case for repositioning of existing mTORc1 inhibitors

AMPK/mTOR pathway significance in healthy liver and non‐alcoholic fatty liver disease and its progression

Sa1668 Proteomic Analysis of Nonalcoholic Fatty Liver Disease: Attenuation of Coactosin-like Protein-1 Protects Liver from Steatosis and Injury

Long Noncoding RNAs in the Mtor Signaling Network: Biomarkers and Therapeutic Targets

Lipid metabolism, inflammation, and foam cell formation in health and metabolic disorders: targeting mTORC1

Role of Mechanistic Target of Rapamycin in Autophagy and Alcohol-Associated Liver Disease

mTOR Signaling, Function, Novel Inhibitors, and Therapeutic Targets

Role of the mTOR-autophagy-ER stress pathway in high fructose-induced metabolic-associated fatty liver disease

Mechanistic Target of Rapamycin Complex 1: From a Nutrient Sensor to a Key Regulator of Metabolism and Health

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Abstract 2804: Metabolic-immunoregulatory role of CCRK-mTOR signaling in NAFLD-associated hepatocellular carcinoma

Molecular Mechanism Pathways of Natural Compounds for the Treatment of Non-Alcoholic Fatty Liver Disease

Mtorc1 Signaling in Hepatic Lipid Metabolism

The Upstream Pathway of mTOR-Mediated Autophagy in Liver Diseases

Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease

Emerging novel targets for nonalcoholic fatty liver disease treatment: Evidence from recent basic studies

MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease